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Intestinal alterations in IBD are triggered and maintained by an overexpression of proinﬂammatory cytokines. Additionally,
increased immune activation has been found in the adjacent intestinal areas without displaying any apparent histological
alterations, however, the regulatory environment is not well established. Biopsy specimens from patients with ulcerative colitis
(UC) and Crohn’s disease (CD), from both aﬀected and unaﬀected areas, and also from a group of colonic biopsies from healthy
controls, were included in our study. Cytokines and markers of mucosal damage were analyzed by real-time PCR, and some of the
results conﬁrmed by western-blot and ELISA. Levels of IFNγ,T N F α, IL-6, IL-15, IL-18, and IL-23 were increased (above healthy
controls) in both aﬀected and unaﬀected areas from IBD. IL-1β, IL-6, IL-12, and IL-27 were higher in aﬀected areas compared to
unaﬀected ones in UC but not CD. In general, a correlation was observed between mRNA levels of these cytokines and both iNOS
andGranzymeB.SOCS-2andSOCS-3werealsoincreasedintheaﬀectedareas.Inconclusion,theunaﬀectedareasfromIBDshow
increased levels of a restricted set of cytokines that may exert immune activating roles in these areas without being able to trigger
tissue damage.
Copyright © 2009 Alberto J. Le´ on et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Ulcerative colitis (UC) and Crohn’s disease (CD) are severe
intestinal inﬂammatory conditions which result from a
dysregulated proinﬂammatory response to components of
the gut microﬂora, inadequately controlled by normal
regulatory/homeostatic mechanisms [1]. The expression of
proinﬂammatory cytokines is increased in inﬂammed biopsy
areas from both UC and CD, and the eﬀect of these cytokines
on the intestine has been directly related with the induction
of tissue injury (destruction) [2, 3].
Most of the reports published so far on these chronic
inﬂammatory diseases are mainly focused on the patho-
logical events occurring in areas of the intestine with a
histologically altered mucosa. However, there is evidence
suggesting that the unaﬀe c t e dt i s s u ea r e a so fI B Du n d e r g o
an abnormal immune activation as shown by the expression
of increased levels of the proinﬂammatory cytokines IL-6,
TNFα [4], and IL-18, in intestinal biopsies from CD patients
[5]. Contrary to CD, where the involvement of unaﬀected
areas is better known, further studies are needed to conﬁrm
the presence of inﬂammatory mediators in the unaﬀected
tissue areas from UC.2 Mediators of Inﬂammation
The increase in proinﬂammatory cytokines and mark-
ers of mucosal damage in the aﬀected areas of IBD
is wellestablished. Diﬀerent eﬀector mechanisms may be
activated during intestinal inﬂammation, such as inducible
nitric oxide synthase (iNOS), a key inﬂammatory mediator
which increases NO levels [6] and is involved in the
control of mucosal damage [7, 8]; the apoptosis-related
molecule Granzyme B (GZNB) [9, 10]; the extracellular
matrix-remodelling molecule, MMP-3 and its physiological
inhibitor TIMP-1 [11]. However, little is known about which
cytokines induce these eﬀector mechanisms in the aﬀected
areas of IBD. Additionally, the regulatory activities of the
immune response, through mediators such as IL-10 and
TGFβ, still need to be proﬁled, especially those that might
take place in the unaﬀected areas. Moreover, the SOCS-
mediated intracellular suppressor activity exerts a crucial
negative feedback of the cytokine signaling, and it may play
a relevant role in the control of the mucosal damage in IBD
[12].
Our aims were (1) to study the expression of cytokines
and markers of tissue damage in aﬀected and unaﬀected
tissue areas from IBD, (2) to correlate cytokine proﬁles
to potential activation mechanisms of mucosal damage in
the intestine from these chronic inﬂammatory diseases, and
(3) to determine the potential role of diﬀerent regulatory
mediators, including certain cytokines and SOCS family
members, in the preservation of histological integrity in
unaﬀected tissue areas.
2.MaterialsandMethods
2.1. Study Subjects. Patients attended the Adult Gastroen-
terology Clinics, from the Hospital Cl´ ınico Universitario and
Hospital Universitario R´ ıo-Hortega of Valladolid (Spain),
as part of the routine diagnostic procedures for suspicion
of IBD, during years 2003 to 2005. Intestinal biopsies were
obtained during colonoscopy using a ﬁberscope with forceps
(Olympus, Tokyo, Japan). Patients’ diagnosis was initially
based on the endoscopic ﬁndings and later conﬁrmed by
histopathological analysis of biopsies taken from aﬀected
areas. The unaﬀected areas from which biopsies were col-
lected were deﬁned by endoscopic evaluation histopatho-
logical analysis of these biopsies could not be performed
due to the limited amount of tissue that was collected,
which required to be totally disrupted for RNA/protein
puriﬁcation. The Montreal classiﬁcation [13]w a su s e dt o
deﬁne the clinical features of patients. Informed consent was
obtained from patients, and the study protocol was approved
by the local Ethics Committee (University Hospital, Faculty
of Medicine).
Two intestinal biopsy specimens were collected from
patients with IBD, one from aﬀected areas and a second
one from areas without endoscopic alterations. Study groups
were composed as follows (Table 1): UC from aﬀected (n =
26)andunaﬀectedareas(n = 22),CDfromaﬀected(n = 16)
and unaﬀected (n = 15), and a group of healthy controls
(n = 16), from patients submitted to the hospital for
screening or followup of other colon diseases (mostly colon
cancer), but not presenting signs of mucosal inﬂammation
or disease.
The group of patients with UC (26 cases) has an average
age of disease onset of 42.3 years, treatment was 5-ASA (14
cases), corticoids (2 cases), and untreated (10 cases). The
degree of mucosal damage in the aﬀected areas of UC was
mild (5 cases), moderate (9 cases), and severe (12 cases).
The group of CD patients (16 cases) has an average age
of disease onset of 37.1 years, they showed the following
presentations:penetrating(3cases),stricturing(2cases),and
nonpenetrating and nonstricturing (formerly inﬂammatory
presentation, 10 cases). At the time of biopsy collection, 4
cases were untreated and none of the patients was receiving
immunouppressors (detailed description on the treatments
is shown in Table 1).
2.2. Sample Preparation. After collection, tissue samples
were immediately submerged in 1mL of RNA-Later solution
(Ambion,Austin,TX,USA)andstoredat −20
◦C .Bothtotal
RNA and protein samples were isolated from biopsies using
TRIZOL reagent following manufacturer’s instructions. Pro-
tein samples were diluted in SDS 1%, and total protein
concentration was determined using the DC Protein Assay
(BioRad Laboratories, Hercules, CA, USA).
2.3. Quantitative Polymerase Chain Reaction. Quantiﬁcation
of mRNA expression in intestinal biopsies was performed as
previously described [14]. Brieﬂy, reverse transcription was
carried out by using the SuperScript First-Strand Synthesis
System for reverse transcriptase (RT)-PCR Kit (Invitrogen
SA, Barcelona, Spain) using OligodT primers and mRNA
levels were determined by real-time PCR using a LightCycler
instrument (Roche Applied Science, Mannheim, Germany).
Reactions were performed in a volume of 20μL using
either FastStart SYBR Green MasterMix (Roche) or FastStart
HybProbes MasterMix (Roche) for Taqman probes, and 1μL
of thermolabile Uracil DNA Glycosylase (UDG) (Roche) to
prevent carry-over contamination. Cytokine primer sets are
described in Table 2. Samples were analyzed in triplicate and
results, obtained as a ratio cytokine/β-actin mRNA levels,
were expressed as arbitrary units.
A standard curve for each gene was made using serial
dilutions from the RNA extracted from cell lines, either
Jurkatt (6 × 106 cells) or Thp1 (10 × 106 cells), previously
stimulated with 10nM of PMA and 3uM of Ionomycin for 5
hours.
2.4. Western-Blot Analysis. In all cases, 10μgo fp r o t e i n
was added per well, and separated by using a 15% acril-
amide/bisacrilamide (37.5 : 1) gel in a mini-Protean II
(BioRad), and transferred onto PVDF membranes of 0.45
Micron (Pierce Biotechnology, Rockford, IL, USA). Mem-
braneswereincubatedwithprimaryantibodiestohumanIL-
15 (mouse monoclonal MAB247, R&D, Minneapolis, MN,
USA) or IL18 (mouse monoclonal SC-13602, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) at a ﬁnal dilution
of 1/400 and 1/200, respectively; a second incubation withMediators of Inﬂammation 3
Table 1: Clinical information from IBD patients included in the study according to the Montreal classiﬁcation [13]. Age groups: A2 17–40
years,andA3>40years.UCaﬀectedarea:E1proctitis,E2leftcolitisorrectosigmoditis(E2-RS),andE3pancolitis.UCgrade:S1mildcolitis,
S2 moderate colitis, and S3 severe colitis. CD aﬀected area: L1 terminal ileon, L2 colon, L3 ileocolonic, and “p” periananal aﬀectation. CD
presentation: B1 nonstricturing and nonpenetrating (formerly known as inﬂammatory), B2 stricturing, and B3 penetrating.
Ulcerative colitis
Case No. Age group Sex Biopsy availability
(aﬀected/unnafected areas)
UC grade Aﬀected area Treatment
UC-1 A3 M Both S1 E2-RS 5-ASA
UC-2 A2 M Both S3 E2-RS None
UC-3 A2 M Both S3 E2 None
UC-4 A3 M Both S1 E2 5-ASA
UC-5 A3 M Both S3 E2 None
UC-6 A3 M Both S2 E1 None
UC-7 A2 F Both S3 E2 None
UC-8 A3 M Both S3 E1 5-ASA
UC-9 A2 M Both S2 E1 None
UC-10 A3 M Both S1 E1 5-ASA
UC-11 A2 M Both S2 E3 Methylprednisone
UC-12 A3 M Both S3 E2 None
UC-13 A2 M Both S2 E1 5-ASA
UC-14 A2 M Both S1 E2-RS None
UC-15 A3 M Both S2 E2 Methylprednisone
UC-16 A3 F Both S3 E1 5-ASA
UC-17 A2 M Both S3 E1 5-ASA
UC-18 A3 M Both S3 E3 5-ASA
UC-19 A2 M Both S2 E2 5-ASA
UC-20 A2 F Both S3 E1 None
UC-21 A3 M Both S3 E2 5-ASA
UC-22 A3 F Both S1 E2-RS None
UC-23 A2 F Aﬀec. only S3 E3 5-ASA
UC-24 A2 F Aﬀec. only S2 E2 5-ASA
UC-25 A3 M Aﬀec. only S2 E2 5-ASA
UC-26 A3 M Aﬀec. only S2 E1 5-ASA
Crohn’s disease
Case No. Age group Sex Biopsy availability
(aﬀected/unnafected areas)
CD presentation Aﬀected area Surgery Treatment
CD-1 A2 M Both B1 L1 No None
CD-2 A3 F Both B2 L1 No None
CD-3 A3 M Both B3 L2 Yes Budesonide
CD-4 A2 F Both B1p L1 Yes Topic steroids + 5-ASA
CD-5 A2 M Both B1 L1 No Oral steroids
CD-6 A2 M Both B1 L2 No 5-ASA
CD-7 A2 M Both B3 L3 Yes Budesonide +5-ASA
CD-8 A3 F Both B1p L1 Yes Topic steroids + 5-ASA
CD-9 A2 F Both B2 L1 No None
CD-10 A2 F Both B1 L1 No 5-ASA
CD-11 A2 F Both B1 L1 No 5-ASA
CD-12 A3 M Both B3 L1 No 5-ASA
CD-13 A2 F Both B1 L1 No 5-ASA
CD-14 A2 F Both B1 L1 No None
CD-15 A2 M Both B1p L3 Yes Topic 5-ASA
CD-16 A3 M Aﬀec. only B1 L1 No 5-ASA4 Mediators of Inﬂammation
Table 2: Real-time PCR information. Primer sequences, PCR products length, temperature of annealing, and source of the primers used for
Quantitative PCR.
Gene Forward primer (5 -3 ) Reverse primer (5 -3 )
PCR product
length (base
pairs)
Annealing
temperature Primer source
β-actin atg ggt cag aag gat tcc tat gtg ctt cat gag gta gtc agt cag gtc 359 60 M. Bongers, E. Liehl, J. Barsig,
Focus 21, 66 (2006)
GZMB aag acg act tcg tgc tga ca ccc caa ggt gac att tat gg 62 60 Universal Probe Library
Human#60 (Roche)
IFNγ tgg aaa gag gag agt gac ag att cat gtc ttc ctt gat gg 129 60
M. G. Karlsson, J. Ludvigsson,
Diabetes Res. Clin. Pract. 40,
21 (1998)
IL-1β t c cg a cc a cc a ct a ca g c g ga g cg t gc a gt t ca 224 53
Designed with the software
LightCycler Probe Design 2
(Roche)
IL-4 ttc tac agc cac cat gag cat gat cgt ctt tag cct ttc 198 59
Designed with the software
LightCycler Probe Design 2
(Roche)
IL-6 Commercial reagent —6 0
TaqMan Gene Expression
Assay Hs00174131 ml
(Applied Biosystems)
IL-10 Commercial reagent —6 0
TaqMan Gene Expression
Assay Hs00174086 ml
(Applied Biosystems)
IL-12(p35) tgt cac cga gaa gct gat gt gag gtt tct ggc caa act ga 278 68
Designed with the software
LightCycler Probe Design 2
(Roche)
IL-12(p40) Commercial reagent —6 0
TaqMan Gene Expression
Assay Hs00233688 ml
(Applied Biosystems)
IL-15 tgt ctt cat ttt ggg ctg ttt ca tcc tcc agt tcc tca cat tct ttg 327 60 C. Kebelmann-Betzing et al.,
Cytokine 13, 39 (2001)
IL-18 gcttga atc taa att atc agt c caa att gca tct tat tat cat g 335 55 T. Tomita et al., J. Infect. Dis.
183, 620 (2001)
I L - 2 3 ( p 1 9 ) a g ca g ct c aa g ga t gg c ac t ca g c c cc a aa t tt c cc t tc c ca t ct a 251 55 A. Wesa et al, BMC Immunol.
3, 14 (2002)
IL-27(p28) gcg gaa tct cac ctg cca gga aac atc agg gag ctg ctc 69 64 S. Pﬂanz et al, Immunity 16,
779 (2002)
iNOS tct gca gac acg tgc gtt act atg cac agc tga gca ttc ca 115 56 M. Ohtsuki et al., Clin. Chim.
Acta 353, 103 (2005)
MMP-3 gaa atg cag aag ttc ctt gg gtg aaa gag acc cag gga gtg 489 60 T. Sadowski, J. Steinmeyer,
Inﬂamm. Res. 50, 175 (2001)
SOCS-2 agt gtg gtt cat ctg atc g aca ttt gtt aat ggt gag cct 162 54
Designed with the software
LightCycler Probe Design 2
(Roche)
SOCS-3 ggc cac tct tca gca tct c atc gta ctg gtc cag gaa ctc 109 62 N. Torpey et al, J. Biol. Chem.
279, 26789 (2004)
S O C S - 4 c c ta t ga c tg g ct c tg t g c tt c gg c tg c gt a tt 269 52
Designed with the software
LightCycler Probe Design 2
(Roche)
SOCS-5 cct aca ggt gtt cag taa gac cca cac tgt tga aat act cat cc 171 56
Designed with the software
LightCycler Probe Design 2
(Roche)
TGFβ1 gga cac caa cta ttg ctt cag tcc agg ctc caa atg tag g 148 60 W. X. Chen et al., World J.
Gastroenterol. 8, 379 (2002)
TIMP-1 Commercial reagent —6 0
TaqMan Gene Expression
Assay Hs00171558 ml
(Applied Biosystems)
TNFα tca gat cat ctt ctc gaa cc cag ata gat ggg ctc ata cc 361 60 G. J. Atkins et al., Bone 26, 653
(2000)Mediators of Inﬂammation 5
antibodies to mouse IgG labelled with horseradish perox-
idase (Amersham Biosciences Europe, Freiburg, Germany),
using the chemiluminiscent substrate ECL Plus (Amersham)
and the autoradiography ﬁlm Hyperﬁlm ECL (Amersham).
Finally, the QuantityOne software (BioRad) was used for
molecular weight and densitometric analysis of the bands.
Recombinant human IL-15 (Peprotech, London, UK) and
IL-18 (active form) (Chemicon, Temecula CA, USA) were
used as positive controls.
2.5. Protein Levels Analyzed by ELISA. To avoid interference,
SDS was removed from each protein extract with the SDS-
out reagent (Pierce), and the ﬁnal protein concentration was
determined by using the DC Protein Assay (BioRad). IFNγ
andTGFβ weremeasuredin50μgoftheproteinextractfrom
biopsies, using speciﬁc Easy Elisa (Amersham) tests. Finally,
theabsorbancewasmeasuredbyaSunriseELISAplatereader
(Tecan, Zurich, Switzerland).
2.6. Statistical Analysis. Results are expressed as the median
value and the interquartile range. Statistical diﬀerences in
cytokine mRNA expression levels between groups were
analyzed using the Mann-Whitney U-test, and conﬁrmed
with the Kruskal Wallis test with Dunn’s posttest. Both tests
showed almost identical conclusions (Table 3), the results
of this paper are based on the ﬁrst one. The analysis
of nonparametric correlation was performed by using the
Spearman’s rank correlation test. A value of P<. 05 was
consideredstatisticallysigniﬁcant.Thestatisticalanalysiswas
performed by using the software program SPSS-16.0.
3. Results
3.1. Mediators of Tissue Injury (iNOS, GZMB, and MMP-3)
Are Upregulated in Aﬀected Areas of IBD. In biopsies from
patientswithUC,bothMMP-3andTIMP-1mRNAlevelsare
increased in aﬀected areas, as compared to healthy controls
(P = .018andP = .001,resp.)(Figure 1),whereasunaﬀected
showed no changes. Moreover, iNOS and GZMB were also
increased at the mRNA level in aﬀected (P<. 001 and
P = .006, resp.), but not unaﬀected areas. In biopsies from
patients with CD, mRNA levels of iNOS are increased above
healthy controls in both aﬀected (P<. 001) and unaﬀected
areas (P = .019), while GZMB was increased only in aﬀected
areas (P = .009). TIMP-1 mRNA levels were also raised
in both aﬀected (P = .043) and unaﬀected areas (P =
.045), from CD patients. No changes in the levels of MMP-
3 were found in CD. When comparing mRNA levels between
aﬀectedareasofUCandCD,iNOS,GZMBandMMP-3show
higher levels in UC (P = .036,.037 and .014, resp.).
No signiﬁcant correlations between mRNA levels of
m o l e c u l e si n v o l v e di nt i s s u ed a m a g e( i N O S ,G Z M B ,o r
MMP-3), and the histological score of mucosal damage of
the aﬀected areas were found in either UC or CD, moreover,
cytokine mRNA levels did not correlate with the histological
score. There were no signiﬁcant ﬁndings when comparing
groups of samples according to their clinical presentation of
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Figure 1: Diﬀerences in mRNA levels between study groups,
(a) tissue injury-related molecules, (b) SOCS family members.
Statistical diﬀerences when compared to healthy controls
∗P <. 05
and
∗∗P <. 001, and between aﬀected and unaﬀected areas from
the same pathology
††P <. 001. U: arbitrary units.
CD or the treatment, probably due to the small amount of
samples on each subgroup (data not shown).
3.2. Proinﬂammatory Cytokines (IFNγ,T N F α, IL-6, IL-15, IL-
18 and, IL-23) Are Increased in Both Aﬀected and Unaﬀected
Areas. IFNγ and TNFα mRNA levels are increased above
healthy controls in UC from aﬀected (P = .046 and P =
.005, resp.) and unaﬀected areas (P = .038 and P =
.004) as compared to healthy controls (Figure 2). Also in
biopsies from CD patients, IFNγ and TNFα mRNA levels
were signiﬁcantly increased in aﬀected areas (P = .024 and
P = .029) and unaﬀected areas (P = .027 and P = .004).
Protein levels of IFNγ measured by ELISA were found to6 Mediators of Inﬂammation
Table 3: Overview of mRNA expression in intestinal biopsies from UC and CD patients. ↑, ↓,a n d=: increased, decreased, or unchanged
mRNA levels respect to healthy controls, Mann-Whitney P < .05.
Ulcerative colitis Crohn’s disease
Aﬀected Unaﬀected Aﬀected Unaﬀected
Mediators of mucosal damage
GZMB ↑=↑ =
iNOS ↑=↑ =
MMP-3 ↑===
TIMP-1 ↑=↑ =
Proinﬂammatory cytokines in aﬀected areas only
IL-1β ↑=↑ =
IL-4 ↑===
IL-12(p35) ↑=↑ =
IL-12(p40) ↑===
IL-27(p28) ↑=↑ =
Cytokines in aﬀected and unaﬀected areas
IFNγ ↑↑↑ ↑
TNFα ↑↑↑ ↑
IL-6 ↑↑↑ ↑
IL-15 WB ↑/mRNA ↑ WB ↑/mRNA ↑ WB ↑/mRNA = WB ↑/mRNA =
IL-18 WB ↑/mRNA ↑ WB ↑/mRNA ↑ WB ↑/mRNA ↑ WB ↑/mRNA =
IL-23(p19) =↑ ↑ ↑
SOCS family
SOCS-2 ↑===
SOCS-3 ↑↑↑=
SOCS-4 ↑===
SOCS-5 === =
Regulatory cytokines
IL-10 =↓==
TGFβ1 === =
be increased above healthy controls (4.350[3.075]) in both
aﬀected (10.000[5.938], P = .033) and unaﬀected areas
(8.850[6.887], P = .041) from UC, whereas no signiﬁcant
diﬀerences were found in CD (data not shown).
IL-6 levels are increased in both aﬀected and unaﬀected
areas (P<. 001 and P = .002, res.) from UC, and also in
aﬀected and unaﬀected samples from CD patients (P = .010
and 0.004). Increased IL-15 mRNA levels were found in both
aﬀected(P = .003)andunaﬀectedareas(P = .001)fromUC,
compared to healthy controls, but not in CD. At the protein
level (Figure 4), IL-15 expression was found in aﬀected (15
out of 26) and unaﬀected areas (11 out of 22) from UC,
as well as in aﬀected (6 out of 16) and unaﬀected areas (7
out of 15) from CD, but in none of the healthy controls.
IL-18 mRNA expression was increased in UC from aﬀected
(P = .002) and unaﬀected areas (P<. 001), whereas only
a signiﬁcant increase was found in CD from aﬀected areas
(P = .026). At the protein level (Figure 4), the active form of
IL-18 was found expressed in most samples from UC (22 out
of 26 in aﬀected areas, 18 out of 22 in unaﬀected areas) and
CD (12 out of 16 in aﬀected areas, 13 out of 15 in unaﬀected
areas), and only sporadically in healthy controls (2 out of
16). IL-23(p19) mRNA levels were increased in both aﬀected
and unaﬀected areas of CD (P = .012 and P = .020) and
remained unmodiﬁed in UC.
3.3. The Highest Levels of Cytokines (IL-1β, IL-4, IL-6, IL-12,
a n dI L - 2 7 )A r eF o u n di nA ﬀe c t e dA r e a sa n dT h e yC o r r e l a t e
with Markers of Tissue Damage. IL-1β mRNA levels are
increased in aﬀected areas from both UC and CD, above
healthy controls (P = .009 and P = .017, resp.), but also
above unaﬀected tissue areas (P = .008 and P = .004)
(Figure 3). IL-4 mRNA levels are higher in aﬀected areas
from UC, than in healthy controls (P = .009), whereas
diﬀerences between aﬀected and unaﬀected areas are close
to statistical signiﬁcance (P = .056). No changes were
found when CD samples were compared. Although IL-6
is increased in all IBD groups (shown above), its levels
are highest in aﬀected areas from UC (P = .015, versus
unaﬀected), with a 120-fold increase when compared to
healthy controls, and ranging from 6- to 18-fold in other
groups (Figure 2). mRNA levels from both subunits of IL-
12, p35 and p40, have been analyzed. IL-12(p40) is increased
in aﬀected areas of UC above healthy controls (P = .023)Mediators of Inﬂammation 7
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Figure 2: Diﬀerences in mRNA levels of cytokines increased only
in both aﬀected and unaﬀected areas of IBD. Statistical diﬀerences
compared to healthy controls
∗P <. 05 and
∗∗P <. 001, and
between aﬀected and unaﬀected areas from the same pathology
†P <. 05. U: arbitrary units.
and also above unaﬀected areas (P = .015), however, no
changes in IL-12(p40) were observed in CD tissue samples
(Figure 3). However, mRNA levels of the p35 subunit only
were increased in the aﬀected areas of UC (P = .044). Levels
of IL-27(p28) were increased in aﬀected areas of UC above
healthy controls (P = .010) and also above unaﬀected areas
of UC (P = .044), whereas aﬀected areas of CD also showed
increased levels of IL-27 above healthy controls (P = .027).
There are signiﬁcant correlations among levels of these
cytokines (IL-1β, IL-4, IL-6, IL-12(p35 and p40), and IL-27)
and those of mediators of tissue injury (iNOS and GZMB)
in aﬀected areas from UC (Table 4), whereas diﬀerences were
not signiﬁcant in aﬀected areas from CD (data not shown).
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Figure 3: Diﬀerences in mRNA levels of those proinﬂammatory
cytokines which are increased only in the aﬀected areas of IBD.
Statistical diﬀe r e n c e sc o m p a r e dt oh e a l t h yc o n t r o l s
∗P <. 05 and
∗∗P <. 001, and between aﬀected and unaﬀected areas from the
same pathology
†P <. 05
††P <. 001. U: arbitrary units.
When comparing cytokine levels between UC and CD, only
IL-12(p40) and IL-15 were found to be increased in aﬀected
a r e a so fU Cc o m p a r e dt oa ﬀected CD (P = .002 and P =
.026, resp.).
3.4. Levels of SOCS-2 and SOCS-3, but Not SOCS-4 and
SOCS-5, Are Increased in IBD. SOCS-2 mRNA levels are
increased, above healthy controls, in both aﬀected and
unaﬀected areas of UC (P = .003 and P = .041), but no
changes are observed in samples from CD (Figure 1). SOCS-
3 levels were found upregulated in the aﬀected areas of both
UC and CD (P<. 001 and P<. 001), and also in the
unaﬀected areas of UC (P = .027), though to a lesser extent8 Mediators of Inﬂammation
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Figure 4: Western-blot analysis of IL-15 and IL-18 in protein extracts from intestinal biopsies. (a) Representative ﬁgure of several
experiments, analysis of IL-15 (12.9kDa), IL-18 active form (18kDa), and IL-18 inactive form (24kDa). Control lanes “C”: human
recombinant IL-15 or IL-18. Lanes 1–3: healthy controls. Lanes 4-5: aﬀected areas from UC. Lanes 6-7: unaﬀected areas from UC. Lanes
8-9: aﬀected areas from CD. Lanes 10-11: unaﬀected areas from CD. (b) Densitometric band analysis, statistical diﬀerences respect to healthy
controls are shown.
∗∗P <. 05 and
∗P <. 01.
Table 4: Correlation analysis of mRNA levels among cytokines
and eﬀector molecules in aﬀected areas from UC (Spearman’s
correlation rank).
iNOS Granzyme B MMP-3
Proinﬂammatory cytokines in aﬀected areas only
IL-1βP < . 001 P<. 001 N.S.
IL-4 N.S. P = .048 N.S.
IL-12(p35) P = .011 P = .018 N.S.
IL-12(p40) P = .039 P = .020 N.S.
IL-27(p28) P = .037 N.S. N.S.
Cytokines in aﬀected and unaﬀected areas
IFNγ N.S. N.S. N.S.
TNFα N.S. N.S. N.S.
IL-6 P = .001 P = .003 N.S.
IL-15 N.S. P = .021 N.S.
IL-18 N.S. N.S. N.S.
IL-23(p19) N.S. N.S. N.S.
as compared to aﬀected areas from UC samples (P<. 001).
No statistical diﬀe r e n c e si nm R N Al e v e l so fS O C S - 4a n d
SOCS-5 were found among the diﬀerent groups (data not
shown). Although the analysis of SOCS-1 was part of our
initial experimental design, the results were not conclusive,
probably due to technical reasons.
Levels of regulatory cytokines TGFβ and IL-10 were also
analyzed. No diﬀerences were found in TGFβ levels when
study groups were compared, neither at the mRNA, nor at
the protein level, measured by ELISA. No increase in the
IL-10 mRNA levels was found between groups (data not
shown).
4. Discussion
Inﬂammatory bowel disease (IBD) is thought to be caused
by an uncontrolled response to components of the intestinal
ﬂora,whichmay aﬀectindividuals withgenetic susceptibility
togetherwithotherenvironmentalfactors[15].Theimmune
activation in aﬀected tissue areas initiates the pathological
process by activation of diﬀerent cell types of the immune
system, induction of cell inﬁltrate and increased apoptosis
levels altogether produce major alterations in the tissue
architecture of the intestine [3].
Our results conﬁrm that aﬀected areas from UC and
CD display a high expression pattern of proinﬂammatoryMediators of Inﬂammation 9
cytokines, including IFNγ,T N F α,I L - 1 β, IL4, IL-6, IL-12, IL-
15, IL-18, IL-27 (Figures 2 and 3) and also molecules directly
related with tissue injury, such as iNOS, GZMB, and MMP-3
(Figure 1). Despite the wide range of upregulated cytokines,
only IL-1β, IL-4, IL-6, and IL-12 showed positive correlation
with the levels of iNOS and GZMB at their mRNA levels
(Table 4). These results are in accordance with other reports
suggesting that IL-1β and IL-6 are directly involved in the
regulation of mucosal damage, in both UC and CD [16], and
also in animal models [17].
On the other hand, overexpression of proinﬂammatory
immune mediators is not an exclusive feature of areas with
histological alterations, previous studies have shown that
the unaﬀected areas can also display a proinﬂammatory
environment [18]. It has been suggested that CD is featured
by an increased degree of immune activation aﬀecting wide
areas of the intestine, while those showing pathological
alterations correspond to speciﬁc intestinal areas where
the mechanisms of mucosal damage are triggered [4]. We
can deﬁne a group of cytokines (IFNγ,T N F α,I L - 6 ,I L -
15, IL-18, and IL-23) characterized by increased levels of
expression (above healthy controls) in the aﬀected areas
and, moreover, their expression is also increased in areas
without histological alterations. However, the presence of
this cytokines in the unaﬀected areas may not be suﬃcient
to trigger mechanisms of mucosal damage. In fact, increased
levels of TNFα [19]a n dI L - 1 5[ 20] have been previously
reportedinintestinalbiopsiesfromIBDpatientsinremission
without biopsy alterations. The implication of IFNγ and
TNFα in the pathogenesis of IBD has been well stablished,
however, they may also require the presence of other
cytokines, such as IL-12, in order to activate the whole array
of functions that induce mucosal damage displayed in the
aﬀected areas.
Once the release of immune mediators in the unaﬀected
areas has been initiated, the question of why these areas
do not display histological alterations should be addressed.
The SOCS-mediated intracellular suppressor activity exerts a
crucial negative feedback of the cytokine signaling. SOCS-1
participates in the control of IFNγ responses in the aﬀected
areasfromIBD[12],ho wev erweha v ebeenunablet oanalyze
its expression levels in the unaﬀected areas from IBD, in
a context where the involvement of the STAT1 pathway is
strongly suggested by the presence of IFNγ.W eh a v ef o u n d
that SOCS-2 is upregulated in both aﬀected and unaﬀected
areasfromUC,butnotCD(Figure 1).Thebiologicalactivity
of SOCS-2 has been closely related to cell growth and
regulation of embryonic development in animal models, but
its connection with cytokine signaling is not clear, and a
more detailed study is required to deﬁne the relevance of
SOCS-2 in IBD pathogenesis. Levels of SOCS-3 are strongly
upregulated in the aﬀected areas from UC and CD, and to a
lesserextent in the unaﬀectedones from UC. This expression
pattern seems to overlap with the observed for IL-6, despite
the lack of correlation between its mRNA levels, and this
suggests the implication of the STAT-3 signaling pathway
in the pathogenesis of IBD, with IL-6 acting as activator
and SOCS-3 as negative regulator [21]. Taken together, these
results suggest that SOCS is not the factors that might
prevent the immune activation in the unaﬀected tissue areas
from being turned into a harmful response.
Other cytokines with regulatory function may have a role
inthehomeostaticmechanismscontrollingmucosaldamage.
Previous studies have found TGFβ to be involved during
periods of active disease [22]. However, we did not ﬁnd
diﬀerences in TGFβ expression (in both mRNA and protein
levels), and this may be related to the high expression of
Smad7 reported by others in these patients [22]. Another
anti-inﬂammatory cytokine, IL-10, was previously found to
be abundantly expressed by macrophages in areas of dense
inﬂammatory inﬁltrate, and it has been directly related with
the attenuation of the mucosal inﬂammation [16]. Contrary
to other studies, our results show a decrease in the mRNA
levels of IL-10 in the aﬀected areas of UC. We believe that
further studies focused on the counter-inﬂammatory side of
immune regulation, including a broader range of regulatory
cytokines and functional studies in animal models, are cru-
cial to fully understand the connection between regulatory
cytokines and the mechanisms of mucosal damage in both
aﬀected and unaﬀected areas of the intestine.
UC and CD are thought to share many mediators
that participate in the induction of mucosal damage [3].
When comparing the gene expression proﬁles between these
two pathologies, microarray analysis revealed overlapping
patterns of upregulated genes that belong to the same
functional groups [23]. However relevant diﬀerences in the
molecular mechanisms that trigger them probably exist. Our
results show that the aﬀected areas from UC and CD show
a similar cytokine proﬁle, sharing most of the upregulated
cytokines. We have conﬁrmed the presence of IL-4 in UC
but not in CD, a distinctive feature previously described [2].
Moreover, the presence of IL-23(p19) in CD alone might
represent a hallmark of the disease, however, IL-23 shares
the p40 subunit with other members of the IL-12 family
making it necessary further studies to fully characterize their
diﬀerentrolesinthepathogenesisofIBD.Ontheotherhand,
we found out that the expression levels of iNOS, GZMB, and
MMP-3 in intestinal biopsies are higher in UC than in CD.
This probably reﬂects that a higher rate of tissue damage
is taking place in the aﬀected areas from UC, and it might
explain that, in most cases, the clinical outcome is faster in
the later, as compared to CD. Another possible explanation is
that mucosal biopsies are taken from the upper layers of the
intestine, thetissuecompartmentin whichtheinﬂammatory
activity concentrates in UC, while in CD, the inﬂammatory
process aﬀects to the whole tissue section of the intestine,
including deeper tissue layers.
In conclusion, a great range of proinﬂammatory
cytokines is upregulated in aﬀected areas from IBD, but
only some of them might be directly involved in triggering
mechanisms of mucosal damage, whereas other cytokines
might have immune-activating roles that can also be exerted
beyond the aﬀected areas of the intestine. These diﬀer-
ential roles should be crucial to design strategies and to
deﬁne targets for therapeutic interventions in UC and CD.
Additionally, we believe that further studies focused on the
counter-inﬂammatory side of immune regulation are crucial
to fully understand the pathogenesis of IBD.10 Mediators of Inﬂammation
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